Meher Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 0.07 K
- Company Age 39 Year, 11 Months
- Open Charges ₹ 4.85 Cr
About Meher Pharma (India)
Meher Pharma (India) Limited (MPIL) is a Public Limited Indian Non-Government Company incorporated in India on 04 February 1985 and has a history of 39 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.07 K .
The company currently has active open charges totaling ₹4.85 Cr.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U99999MH1985PLC035256
-
Company No.
035256
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
04 Feb 1985
-
Date of AGM
-
-
Date of Balance Sheet
-
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Meher Pharma (India)?
Board Members
No Directors or KMP associated with company. Upon reviewing the records, we can confirm that there are no Directors or Key Management Personnel (KMP) associated with this company at present.
Financial Performance of Meher Pharma (India).
Enhance accessibility to Meher Pharma (India)'s financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Meher Pharma (India)?
Unlock access to Meher Pharma (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹48.50 M
₹0
Charges Breakdown by Lending Institutions
- Edelweiss Asset Reconstruction Company Limited : 3.95 Cr
- Punjab National Bank : 0.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Sep 1989 | Edelweiss Asset Reconstruction Company Limited | ₹3.35 Cr | Open |
| 10 Jan 1989 | Edelweiss Asset Reconstruction Company Limited | ₹2.00 M | Open |
| 15 Dec 1988 | Punjab National Bank | ₹4.50 M | Open |
| 16 Nov 1986 | Edelweiss Asset Reconstruction Company Limited | ₹1.50 M | Open |
| 12 Sep 1985 | Edelweiss Asset Reconstruction Company Limited | ₹1.00 M | Open |
How Many Employees Work at Meher Pharma (India)?
Unlock and access historical data on people associated with Meher Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Meher Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Meher Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.